Understanding Patient-Derived Glioblastoma Multiforme Cells’ Proliferation

Glioblastoma multiforme (GBM) is the most common and aggressive type of primary brain tumor. Patients with GBM have a median survival of 15 months. Thus, treating GBM can be achieved by inhibiting the proliferation of the patient-derived cells using leaf extract of B. monnieri.

Summary of Research

Glioblastoma multiforme (GBM) is the most common and aggressive type of primary brain tumor. Patients with GBM have a median survival of 15 months. Current treatments for GBM
are quite limited and research into developing novel therapeutics is warranted. Phytochemical analysis of the plant Bacopa monnieri has revealed high concentrations of terpenoids, a bioactive compound shown to have anti-tumorigenic properties. Considering these properties of terpenoids, it was hypothesized that Bacopa may inhibit GBM cell proliferation in-vitro.

Bacopa crude leaf extract was applied to patient-derived GBM cells & U-87 MG cell line in-vitro. Tested extract concentrations ranged from 4 to 300 μg/mL. After 72 hours of exposure, GBM
cell proliferation was analyzed through a colorimetric WST-1 tetrazolium reduction assay. The results revealed that Bacopa extract inhibited cell proliferation in patient-derived GBM cells
and U-87 MG cell line. The IC50 (50% inhibitory dose) range was between 11 and 33 μg/mL for patient-derived GBM and between 33 and 100 μg/mL for U-87 MG. Data analysis revealed
statistically-significant F-values of 282.8 and 28.9 for the patient-derived GBM and the U-87 MG cells, respectively, with P-values less than 0.001 for both.

In conclusion, Bacopa leaf extract does indeed inhibit the proliferation of patient-derived GBM cells and the U-87 MG cell line, a finding which has never been previously reported or published. With further experimentation, Bacopa has the potential to be used as a novel adjuvant treatment modality, hopefully improving survival rates of GBM-afflicted patients.

Leave a Reply

Understanding Patient-Derived Glioblastoma Multiforme Cells’ Proliferation

Glioblastoma multiforme (GBM) is the most common and aggressive type of primary brain tumor. Patients with GBM have a median survival of 15 months. Thus, treating GBM can be achieved by inhibiting the proliferation of the patient-derived cells using leaf extract of B. monnieri.

Scroll to top